{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'for the 7 days prior to the first dose of investigational product. Period stability limit is defined as', 'the respective mean AM or PM PEF obtained over the last 7 days prior to Dayl There should be', \"at least 4 days' measurement for setting up the stability limit, and the first dosing visit should be\", 'rescheduled until data for 4 days are available.', 'Baseline reliever use will be the mean number of reliever use recorded for the 7 days prior to the', 'first dose of investigational product. Period stability limit is defined as the respective mean AM or', \"PM PFE obtained over the last 7 days prior to Day1. There should be at least 4 days'\", 'measurement for setting up the stability limit, and the first dosing visit should be rescheduled until', 'data for 4 days are available for both measurements.', 'Information derived from the electronic PEF meter will be evaluated by the Investigator at study', 'visits.', '9.2.2.2.2 Asthma Symptom Numerical Rating Scale (NRS) Score', 'Parent(s)/caregiver(s)/legal guardian(s) will record overall symptom scores in an electronic', \"diary/PEF meter twice a day prior to measuring PEF. The patient's overall asthma symptoms\", 'experienced during the waking hours will be recorded in the evening (PM symptom score).', 'Baseline symptom scores will be the mean AM and mean PM scores recorded for the 7 days prior', 'to randomization. The baseline AM/PM symptom score will be computed following the same', 'algorithm used for baseline AM/PM PEF. Scores range between 0-4 with 0 indicating more mild', 'symptoms and 4 indicating more severe symptoms. There is no global score, just an AM score and', 'a PM score. A Minimal clinically important difference (MCID) of 0.35 is being used (9) (see', 'Appendix E).', '9.2.2.2.3 Use of Reliever Medicine', 'The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations will be recorded', 'daily by the parent(s)/caregiver(s)/legal guardian(s) in an electronic diary/PEF meter. Each patient', 'should be reminded that salbutamol/albuterol or levosalbutamol/levalbuterol should be used only', 'as needed for symptoms, not on a regular basis or prophylactically. The baseline number of', 'salbutamol/albuterol or levosalbutamol/levalbuterol inhalations/day will be based on the mean of', 'the 7 days prior to randomization.', '9.2.2.3 Health Care Resource Utilization', 'The HCRU questionnaire (questions on use of reliever medication, specialist visit, hospitalization,', \"emergency or urgent medical care facility visit, outcome, school days' loss, etc), as integrated part\", 'of the e-CRF, will be administered as shown in Section 1.2, and will additionally be used to asses', 'HCRU in the event of any asthma exacerbation: severe asthma exacerbation event or evidence of', 'LOAC (for detailed definitions see Section 9).', 'Property of the Sanofi Group - strictly confidential', 'Page 63', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '9.2.2.4 Patient Reported Outcomes, Including Health Related Quality of Life (Secondary', 'Endpoints)', 'Patients will be administered the following PRO questionnaires by their', 'parent(s)/caregiver(s)/legal guardian(s) or with their help. The interviewer administered versions', 'are only for children: ACQ-IA, paediatric asthma quality of life questionnaire (PAQLQ[S]-IA)', 'and will be administered by an interviewer (clinic staff designated by Investigator).', '9.2.2.4.1 Asthma Control Questionnaire-Interviewer Administered', 'The ACQ-IA was designed to measure both the adequacy of asthma control and change in asthma', 'control, which occurs either spontaneously or as a result of treatment, and will be used for', 'children 6 years to <12 years old at Screening.', '9.2.2.4.1.1 ACQ-7-IA (Asthma Control Questionnaire-Interviewer Administered, 7-question', 'version)', 'The Asthma Control Questionnaire-Interviewer Administered, 7-question version (ACQ-7-IA)', 'has 7 questions, with the first 5 items of ACQ-7 (ACQ-5-IA score) addressing the most common', 'asthma symptoms: 1) frequency in past week awoken by asthma during the night, 2) severity of', 'asthma symptoms in the morning, 3) limitation of daily activities due to asthma, 4) shortness of', 'breath due to asthma and 5) wheeze. And with 2 questions on overall reliever medication use', '6) short-acting bronchodilator use, and - after spirometry assessment - current asthma status:', '7) predicted bronchodilator use of FEV1 (pre-bronchodilator use, % and % predicted use).', 'Patients and/or parent(s)/caregiver(s)/legal guardian(s) are asked to recall how their asthma and/or', \"their child's asthma, respectively, has been during the previous week and to respond to the\", 'symptom questions 1) to 6) on a 7-point scale (0 = no impairment, 6 = maximum impairment).', 'After spirometry assessment, patients and/or parent(s)/caregiver(s)/legal guardian(s) are asked to', \"recall how their asthma and/or their child's asthma has been during the previous week and to\", 'respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment,', '6= maximum impairment). Clinic staff scores the % predicted FEV1 on a 7-point scale based on', 'the pre-central reading spirometry result displayed immediately after the testing. Then, the', 'questions are equally weighted and the global ACQ-7 score is the mean of the 7 questions and', 'therefore between 0 (totally controlled) and 6 (severely uncontrolled) (see Appendix F).', 'Higher score indicates lower asthma control. Patients with a score below 1.0 reflect adequately', 'controlled asthma and patients with scores above 1.0 reflect inadequately controlled asthma. On', 'the 7-point scale of the ACQ-7, a change or difference in score of 0.5 is the smallest change that', 'can be considered clinically important, corresponding to the MCID defined by the developer.', 'For statistical analysis, ACQ-7 global score is calculated by the sponsor using the BMS post', 'central reading value of the %predicted FEV1 for the question 7 of the questionnaire.', 'Measurement properties such as reliability and ability to detect change have been documented in', 'the literature.', 'Property of the Sanofi Group - strictly confidential', 'Page 64', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}